Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires 20,290 Shares of Stock

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) CEO Peter Luo bought 20,290 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were bought at an average price of $3.15 per share, with a total value of $63,913.50. Following the transaction, the chief executive officer directly owned 88,535 shares in the company, valued at $278,885.25. This trade represents a 29.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Peter Luo also recently made the following trade(s):

• On Wednesday, August 5th, Peter Luo acquired 279 shares of Adagene stock. The shares were bought at an average price of $3.65 per share, with a total value of $1,018.35.
• On Tuesday, August 4th, Peter Luo bought 22,966 shares of Adagene stock. The stock was purchased at an average price of $3.65 per share, for a total transaction of $83,825.90.

Adagene Stock Up 6.7%

NASDAQ:ADAG opened at $3.17 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 5.02. Adagene Inc. Sponsored ADR has a 12 month low of $1.30 and a 12 month high of $4.85. The company’s 50-day moving average price is $3.69 and its two-hundred day moving average price is $3.72.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Chardan Capital initiated coverage on Adagene in a research report on Thursday, September 10th. They issued a “buy” rating and a $9.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of Adagene in a research report on Tuesday, July 14th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Adagene in a report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adagene in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Adagene has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Adagene stock. Fifth Lane Capital LP boosted its position in shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG) by 427.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 145,000 shares of the company’s stock after purchasing an additional 117,500 shares during the quarter. Fifth Lane Capital LP owned about 0.31% of Adagene worth $274,000 as of its most recent filing with the Securities and Exchange Commission. 9.51% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Adagene

Here are the key news stories impacting Adagene this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $7 price target. The target implies meaningful upside from recent trading levels and provides a positive signal for investor sentiment. Adagene Earns Buy Rating from HC Wainwright
• Positive Sentiment: HC Wainwright raised its projected loss estimates for fiscal 2027 through fiscal 2030, forecasting losses of $0.42, $0.70, $1.07 and $0.87 per share, respectively, compared with previously wider losses. The revisions suggest improved expectations for Adagene’s longer-term financial performance. Adagene analyst estimates
• Positive Sentiment: At the H.C. Wainwright conference, Adagene highlighted its high-dose CTLA-4 therapy, keeping investor attention focused on the company’s antibody-immunotherapy pipeline and potential clinical value. Adagene at H.C. Wainwright conference
• Neutral Sentiment: Adagene also presented at Morgan Stanley’s Global Healthcare Conference, offering additional visibility for its development programs but no clearly disclosed near-term commercial catalyst. Adagene Morgan Stanley conference transcript
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 loss forecast to $0.43 per share from $0.37, indicating weaker near-term earnings expectations. Separately, another report cited a 10.44% reduction in a price target to $10.50, which could temper enthusiasm despite the bullish H.C. Wainwright view. Adagene price target reduced

Adagene Company Profile

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene’s technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.